Xoma proposes follow-on

Xoma Corp. (NASDAQ:XOMA) proposed a follow-on late Thursday underwritten by Credit Suisse; Jefferies; Cowen; Piper Jaffray; and RBC Capital Markets. Xoma's gevokizumab ( XOMA 052) is in Phase III testing for non-infectious uveitis (NIU) and Behcet's uveitis, with top-line data expected next year. Partner Servier (Neuilly-sur-Seine, France) has worldwide rights to develop and commercialize the humanized IgG2 mAb against IL-1 beta for Type II diabetes and cardiovascular indications and rights outside the U.S. and Japan for all other indications. ...